BeiGene's 2025 total revenue reached 38.205 billion yuan, with net profit attributable to the parent company shareholders reaching 1.422 billion yuan.

Press Release (Reporter Zhang Min) — On the evening of February 26, BeiGene, Ltd. (hereinafter referred to as “BeiGene”) released its 2025 performance forecast. During the reporting period, the company’s total revenue reached 38.205 billion RMB, a year-over-year increase of 40.4%. Thanks to growth in product revenue and improved operational efficiency driven by cost management, net profit attributable to the parent company’s owners reached 1.422 billion RMB.

During the reporting period, BeiGene’s product revenue totaled 37.77 billion RMB, a 39.9% increase year-over-year, mainly due to sales growth of BeiGene’s Zepzelca (Zebutinib), as well as licensed products from Amgen and BeiGene’s own Byezance (Tirrelizumab).

Among these, Zepzelca achieved a new high in revenue, with global sales reaching 28.067 billion RMB, a 48.8% increase year-over-year. Regionally, in the U.S. market, Zepzelca’s annual sales reached 20.206 billion RMB, up 45.5%. In Europe, annual sales were 4.265 billion RMB, a 66.4% increase. In China, annual sales amounted to 2.472 billion RMB, a 33.1% increase.

The announcement states that Zepzelca is the most widely approved BTK inhibitor for indications worldwide. Currently, Zepzelca has been approved in over 75 markets globally. At the 2025 American Society of Hematology (ASH) Annual Meeting, BeiGene announced six-year follow-up data from the Phase 3 SEQUOIA trial and long-term results from the ALPINE trial, further confirming that Zepzelca provides sustained benefits in treating newly diagnosed and relapsed/refractory CLL/SLL adult patients. In the first half of 2026, BeiGene plans to conduct an interim analysis of the Phase 3 MANGROVE trial, comparing Zepzelca combined with Rituximab versus Bendamustine combined with Rituximab for first-line treatment of adult patients with mantle cell lymphoma.

Another core product, Byezance, also saw steady sales growth, with global sales reaching 5.297 billion RMB in 2025, an 18.6% increase year-over-year. Currently, Byezance has been approved in over 50 markets worldwide, with increasing patient accessibility. The company expects to submit applications for additional indications—specifically, Byezance combined with Zanidatamab for first-line treatment of HER2-positive gastric and esophageal adenocarcinoma in the U.S. and China in the first half of 2026. It also anticipates obtaining regulatory approval in Japan for first-line treatment of gastric cancer patients in the second half of 2026.